Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd)

In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab.

The discussion covered:
•⁠  ⁠Overview of the treatment landscape for biliary tract cancer
•⁠  ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue
•⁠  ⁠Management strategies for adverse events, including dose reductions and supportive care
•⁠  ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions
•⁠  ⁠The importance of biomarker testing and patient-centered care in treatment decisions

Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!